Literature DB >> 18332850

K(ATP) channel expression and pharmacological in vivo and in vitro studies of the K(ATP) channel blocker PNU-37883A in rat middle meningeal arteries.

K B Ploug1, L J Boni, M Baun, A Hay-Schmidt, J Olesen, I Jansen-Olesen.   

Abstract

BACKGROUND AND
PURPOSE: Dilatation of cerebral and dural arteries causes a throbbing, migraine-like pain, indicating that these structures are involved in migraine. Clinical trials suggest that adenosine 5'-triphosphate-sensitive K(+) (K(ATP)) channel opening may cause migraine by dilatating intracranial arteries, including the middle meningeal artery (MMA). We studied the K(ATP) channel expression profile in rat MMA and examined the potential inhibitory effects of the K(ATP) channel blocker PNU-37883A on K(ATP) channel opener-induced relaxation of the rat MMA, using the three K(ATP) channel openers levcromakalim, pinacidil and P-1075. EXPERIMENTAL APPROACH: mRNA and protein expression of K(ATP) channel subunits in the rat MMA were studied by quantitative real-time PCR and western blotting, respectively. The in vivo and in vitro effects of the K(ATP) channel drugs on rat MMA were studied in the genuine closed cranial window model and in myograph baths, respectively. KEY
RESULTS: Expression studies indicate that inwardly rectifying K(+) (Kir)6.1/sulphonylurea receptor (SUR)2B is the major K(ATP) channel complex in rat MMA. PNU-37883A (0.5 mg kg(-1)) significantly inhibited the in vivo dilatory effect of levcromakalim (0.025 mg kg(-1)), pinacidil (0.38 mg kg(-1)) and P-1075 (0.016 mg kg(-1)) in rat MMA. In vitro PNU-37883A significantly inhibited the dilatory responses of the three K(ATP) channel openers in rat MMA at 10(-7) and 3 x 10(-7) M. CONCLUSIONS AND IMPLICATIONS: We suggest that Kir6.1/SUR2B is the major functional K(ATP) channel complex in the rat MMA. Furthermore, we demonstrate the potent in vivo and in vitro blocking potentials of PNU-37883A on K(ATP) channel opener-induced relaxation of the rat MMA.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18332850      PMCID: PMC2438990          DOI: 10.1038/bjp.2008.86

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  42 in total

1.  Differential expression of Kir6.1 and SUR2B mRNAs in the vasculature of various tissues in rats.

Authors:  L Li; J Wu; C Jiang
Journal:  J Membr Biol       Date:  2003-11-01       Impact factor: 1.843

Review 2.  Cellular mechanisms regulating [Ca2+]i smooth muscle.

Authors:  C van Breemen; K Saida
Journal:  Annu Rev Physiol       Date:  1989       Impact factor: 19.318

Review 3.  Clinical pharmacology of pinacidil, a prototype for drugs that affect potassium channels.

Authors:  M R Goldberg
Journal:  J Cardiovasc Pharmacol       Date:  1988       Impact factor: 3.105

4.  CGRP may play a causative role in migraine.

Authors:  L H Lassen; P A Haderslev; V B Jacobsen; H K Iversen; B Sperling; J Olesen
Journal:  Cephalalgia       Date:  2002-02       Impact factor: 6.292

5.  The antihypertensive effect of pinacidil versus prazosin in mild to moderate hypertensive patients seen in general practice.

Authors:  B Sterndorff; P Johansen
Journal:  Acta Med Scand       Date:  1988

6.  Pinacidil, a new vasodilator, in the treatment of mild to moderate essential hypertension.

Authors:  V D'Arcy; M Laher; D McCoy; P Sullivan; C H Walsh; M P Hickey
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

7.  Antihypertensive efficacy of pinacidil--automatic ambulatory blood pressure monitoring.

Authors:  P K Zachariah; S G Sheps; A Schirger; L D Fisher; C Shub; J B Collins; R E Spiekerman
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 8.  CGRP antagonists: unravelling the role of CGRP in migraine.

Authors:  Henri Doods; Kirsten Arndt; Klaus Rudolf; Stefan Just
Journal:  Trends Pharmacol Sci       Date:  2007-10-25       Impact factor: 14.819

9.  Potassium channel stimulation in normal subjects and in patients with essential hypertension: an acute study with cromakalim (BRL 34915).

Authors:  D R Singer; N D Markandu; M A Miller; A L Sugden; G A MacGregor
Journal:  J Hypertens Suppl       Date:  1989-12

10.  Attenuation of nocturnal asthma by cromakalim.

Authors:  A J Williams; T H Lee; G M Cochrane; A Hopkirk; T Vyse; F Chiew; E Lavender; D H Richards; S Owen; P Stone
Journal:  Lancet       Date:  1990-08-11       Impact factor: 79.321

View more
  7 in total

Review 1.  The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivatives.

Authors:  Lukas Wanka; Khalid Iqbal; Peter R Schreiner
Journal:  Chem Rev       Date:  2013-02-25       Impact factor: 60.622

2.  Effects of heating coagulation of middle meningeal artery on plasma CGRP level and c-fos expression in migraine rat triggered by nitroglycerin.

Authors:  Xiaofeng Zhu; Yuechen Han; Wenping Xiong; Wenwen Liu; Sumei Lu; Jianfeng Li; Haibo Wang; Zhaomin Fan
Journal:  Neurol Sci       Date:  2011-02-18       Impact factor: 3.307

3.  The KATP channel in migraine pathophysiology: a novel therapeutic target for migraine.

Authors:  Mohammad Al-Mahdi Al-Karagholi; Jakob Møller Hansen; Johanne Severinsen; Inger Jansen-Olesen; Messoud Ashina
Journal:  J Headache Pain       Date:  2017-08-23       Impact factor: 7.277

Review 4.  Brain barriers and their potential role in migraine pathophysiology.

Authors:  Astrid Wiggers; Håkan Ashina; Nouchine Hadjikhani; Abhay Sagare; Berislav V Zlokovic; Martin Lauritzen; Messoud Ashina
Journal:  J Headache Pain       Date:  2022-01-26       Impact factor: 7.277

Review 5.  ATP-Sensitive Potassium Channels in Migraine: Translational Findings and Therapeutic Potential.

Authors:  Amalie Clement; Song Guo; Inger Jansen-Olesen; Sarah Louise Christensen
Journal:  Cells       Date:  2022-08-04       Impact factor: 7.666

6.  Calcium and potassium channels in experimental subarachnoid hemorrhage and transient global ischemia.

Authors:  Marcel A Kamp; Maxine Dibué; Toni Schneider; Hans-Jakob Steiger; Daniel Hänggi
Journal:  Stroke Res Treat       Date:  2012-12-09

7.  The Effect of K ATP Channel Blocker Glibenclamide on CGRP-Induced Headache and Hemodynamic in Healthy Volunteers.

Authors:  Hande Coskun; Fatima Azzahra Elbahi; Mohammad Al-Mahdi Al-Karagholi; Hashmat Ghanizada; Majid Sheykhzade; Messoud Ashina
Journal:  Front Physiol       Date:  2021-06-11       Impact factor: 4.566

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.